Monte Rosa Therapeutics
@monterosatx.com
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more.
These promising findings reinforce our belief in the highly differentiated profile of MRT-8102, the only clinical-stage degrader targeting NEK7, as a potential treatment for cardiovascular and cardiometabolic diseases such as pericarditis, atherosclerosis, and others.
November 8, 2025 at 4:38 PM
These promising findings reinforce our belief in the highly differentiated profile of MRT-8102, the only clinical-stage degrader targeting NEK7, as a potential treatment for cardiovascular and cardiometabolic diseases such as pericarditis, atherosclerosis, and others.
This milestone marks meaningful progress in our immunology and inflammation pipeline – and brings us one step closer to potential new treatment options for patients living with serious inflammatory diseases.
July 21, 2025 at 11:59 AM
This milestone marks meaningful progress in our immunology and inflammation pipeline – and brings us one step closer to potential new treatment options for patients living with serious inflammatory diseases.